


UK (Unit-V) Apixaban Alert Card (Front)



UK (Unit-V) Apixaban Alert Card (Back)

<ul style="list-style-type: none"> ◆ Apixaban may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately. ◆ Treatment with apixaban does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and 	<p>emergency surgery (prothrombin time (PT), international normalised ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.</p> <ul style="list-style-type: none"> ◆ An agent to reverse the anti-factor Xa activity of apixaban is available. <p>DRUGS/AP/50/2009 2085153</p>	<p>Please complete this section or ask your doctor to do it</p>	
<p>Name:</p> <p>Birth Date:</p> <p>Indication:</p> <p>Dose: mg twice daily</p> <p>Doctor's Name:</p> <p>Doctor's telephone:</p>			

58 mm

